Healing Sanctuary Clinic Partners With Cardio Diagnostics Holdings Inc to Offer the Epi+Gen CHD Test in their Medical Practice in Idaho

Rhea-AI Summary

Cardio Diagnostics Holdings (Nasdaq: CDIO) has partnered with Healing Sanctuary Clinic in Idaho to offer the Epi+Gen CHD Precision Cardiovascular Test. This innovative test leverages epigenetics, genetics, and AI to identify patients at risk for coronary heart disease. The collaboration aims to enhance patient outcomes and reduce heart disease incidence in the U.S. Cardio Diagnostics emphasizes its commitment to making precision diagnostics accessible and effective in heart disease prevention.

Positive

• Strategic partnership with Healing Sanctuary Clinic enhances market reach in Idaho.
• Introduction of Epi+Gen CHD test may improve patient outcomes in cardiovascular health.

Negative

• No significant revenue projections or financial data disclosed regarding the partnership impact.
• Dependence on market acceptance and regulatory approvals for the success of the Epi+Gen CHD test.

Leading Medical Practice in Idaho Will be the First Functional Medicine Clinic to Offer the Epi+Gen CHD Precision Cardiovascular Test

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing Sanctuary Clinic, a leading medical practice serving health-forward consumers in Idaho, today announced the availability of Cardio Diagnostics’ Epi+Gen CHD test in Idaho.

As a result of this partnership, Cardio Diagnostics’ Epi+Gen CHD test, which combines epigenetics, genetics, high-throughput computing, and AI to identify those at risk for coronary heart disease, will now be available to eligible patients.

Strategic collaborations between forward-thinking provider organizations and innovative biotechnology companies create knowledge-sharing opportunities that can accelerate the adoption of new medical technologies to supplement current practices and positively impact the well-being of patients.

Dr. Jeffrey Baker, the founder of Healing Sanctuary Clinic, noted that “precision diagnostic tests like Epi+Gen CHD often are the key to ensuring that we are being effective in helping improve the health outcomes of our patients.”

“Cardio Diagnostics is committed to reducing the burden of heart disease by partnering with providers such as Dr. Baker and Healing Sanctuary Clinic, who are committed to leveraging evidence-based, innovative tests to help improve the overall health and wellness of their patients,” shared Cardio Diagnostics CEO, Meesha Dogan, Ph.D.

Through this partnership between Healing Sanctuary Clinic and Cardio Diagnostics to make Epi+Gen CHD available to eligible patients in Idaho, the two organizations are excited to address their mutual goal of decreasing the incidence of heart disease among Americans.

About The Healing Sanctuary

The Healing Sanctuary clinic is a collaboration of health care practitioners dedicated to integrating the highest standard of conventional, complementary, and alternative medicine, nurturing intrinsic healing in the whole person, body, mind, and spirit. The practice offers a new paradigm of patient-centered health care dedicated to furthering evidence-based research and education in integrative and functional medicine. For more information, please visit https://healingsanctuary.clinic/.

About Cardio Diagnostics

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine^TM (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "should," "believe," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™, Cardio’s initial test, is accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s common stock on Nasdaq; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its tests, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that could serve the same or similar functions as the Company’s products and services; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical tests conducted using the Company’s products and services; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005337/en/

Investors:

Meesha Dogan, Ph.D.

CEO

855-226-9991

investors@cardiodiagnosticsinc.com

Media & Public Relations:

Khullani Abdullahi

pr@cardiodiagnosticsinc.com

Source: Cardio Diagnostics Holdings Inc

FAQ

What is the Epi+Gen CHD test offered by Cardio Diagnostics?

The Epi+Gen CHD test is a precision cardiovascular diagnostic tool that uses epigenetics, genetics, and AI to assess the risk of coronary heart disease.

When will the Epi+Gen CHD test be available in Idaho?

The Epi+Gen CHD test is now available to eligible patients through the Healing Sanctuary Clinic in Idaho.

What is the significance of the partnership between Cardio Diagnostics and Healing Sanctuary Clinic?

The partnership aims to enhance access to innovative cardiovascular diagnostics and improve health outcomes for patients at risk of heart disease.

How does Cardio Diagnostics plan to reduce heart disease incidence?

Cardio Diagnostics aims to reduce heart disease incidence by providing precision diagnostics and collaborating with healthcare providers to promote early detection and prevention.

What are the main technologies used in the Epi+Gen CHD test?

The Epi+Gen CHD test combines epigenetics, genetics, high-throughput computing, and artificial intelligence.